Efficacy and safety of oral granisetron versus oral prochlorperazine in preventing nausea and emesis in patients receiving moderately emetogenic chemotherapy

Cancer Journal from Scientific American

Volumn 2, Issue 2, 1996, Pages 85-90

  Burris, H ^a,g   Hesketh, P ^b   Cohn, J ^c   Moriconi, W ^d   Ryan, T ^e   Friedman, C ^f   Fitts, D ^f  

^a BROOKE ARMY MEDICAL CENTER   (United States)

^b ST ELIZABETH'S MEDICAL CENTER   (United States)

^c ALBERT EINSTEIN CANCER CENTER   (United States)

^d St Louis Center for Clinical Research   (United States)

^e Hematol Oncology Consultants Inc   (United States)

^f GLAXOSMITHKLINE   (United Kingdom)

^g University of Texas Health Science Center at San Antonio   (United States)

Author keywords

Moderately emetogenic chemotherapy; Oral granisetron; Oral prochlorperazine

Indexed keywords

ANTIEMETIC AGENT; ANTINEOPLASTIC AGENT; GRANISETRON; PROCHLORPERAZINE;

ARTICLE; CHEMICALLY INDUCED DISORDER; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; MALE; MIDDLE AGED; MULTICENTER STUDY; NAUSEA; NEOPLASM; ORAL DRUG ADMINISTRATION; RANDOMIZED CONTROLLED TRIAL; VOMITING;

ADMINISTRATION, ORAL; ANTIEMETICS; ANTINEOPLASTIC AGENTS; FEMALE; GRANISETRON; HUMANS; MALE; MIDDLE AGED; NAUSEA; NEOPLASMS; PROCHLORPERAZINE; VOMITING;

EID: 0001916215     PISSN: 10814442     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Hesketh PJ, Gandara DR. Serotonin antagonists: a new class of antiemetic agents. J Natl Cancer Inst 1991;83:613-620.
2. Coates A, Abraham S, Kay BB et al. On the receiving end-patient perception of side effects of cancer chemotherapy. Eur J Cancer Clin Oncol 1983;19:203-208.
3. Freeman AJ, Cullen MH. Review article - advances in the management of cytotoxic drug-induced nausea and vomiting. J Clin Pharmacol Ther 1991;16:411-421.
4. Gralla R, Tyson LB, Kris M et al. The management of chemotherapy-induced nausea and vomiting. Med Clin North Am 1987;71:289-301.
5. Chevallier B. Efficacy and safety of granisetron compared with high-dose metoclopramide plus dexamemasone in patients receiving high-dose cisplatin in a single-blind study. Eur J Cancer 1990;26[suppl 1]:S33-S36.
6. Chevallier B. The control of acute cisplatin-induced emesis - a comparative study of granisetron and a combination regimen of high-dose metoclopramide and dexamethasone. Br J Cancer 1993;68:176-180.
7. Cupissol DR, Serrou B, Caubel M. The efficacy of granisetron as a prophylactic anti-emetic and intervention agent in high-dose cisplatin-induced emesis. Eur J Cancer 1990;26:S23-S27.
8. Kamanabrou D. Intravenous granisetron - establishing the optimal dose. Eur J Cancer 1992;28A[suppl 1]:S6-S11.
9. 3 antagonist, in the prevention of nausea and vomiting induced by high dose cisplatin. J Clin Oncol 1994;12:2204-2210.
10. Riviere A. Dose finding study of granisetron in patients receiving high-dose cisplatin chemotherapy. Br J Cancer 1994;69:967-971.
11. Soukop M. A comparison of two dose levels of granisetron in patients receiving high-dose cisplatin. Eur J Cancer 1990;26[suppl 1]:S15-S19.
12. Navari RM, Gandara D, Hesketh P et al. Comparative clinical trial of granisetron and ondansetron in the prophylaxis of cisplatin-induced emesis. J Clin Oncol 1995;13:1242-1248.
13. Ruff P, Paska W, Goedhals L et al. Ondansetron compared with granisetron in the prophylaxis of cisplatin-induced acute emesis: a multicenter double-blind, randomised, parallel-group study. Oncology 1994;5:113-118.
14. 3 antagonist, versus a standard anti-emetic regimen of chlorpromazine plus dexamethasone in the treatment of cytostatic-induced emesis. Eur J Cancer 1990;26[suppl 1]:S28-S32.
15. Smith IE: A comparison of two dose levels of granisetron in patients receiving moderately emetogenic cytostatic chemotherapy. Eur J Cancer 1990;26[suppl 1]:S19-S23.
16. 3 receptor antagonists in the prophylaxis of acute vomiting induced by moderately emetogenic chemotherapy - a randomised study. Eur J Cancer 1993;29A:1669-1672.
17. Noble A, Bremer K, Goedhals L et al, on behalf of the Granisetron Study Group. A double blind, randomised, crossover comparison of granisetron and ondansetron in 5-day fractionated chemotherapy: assessment of efficacy, safety and patient preference. Eur J Cancer 1994;30A:1083-1088.
18. Bleiberg HH, Spielmann M, Falkson G et al. Antiemetic treatment with oral granisetron in patients receiving moderately emetogenic chemotherapy: a dose-ranging study. Clin Ther 1995;17:38-51.
19. Kytril (granisetron HCl) tablets Prescribing Information. King of Prussia, Penn: SmithKline Beecham Pharmaceuticals. 1995;KY:L2T.
20. Hochberg Y, Tamhane AC. Multiple Comparison Procedures. New York: John Wiley, 1987.
21. Agresti A. Categorical Data Analysis. New York: John Wiley, 1990.
22. Johnsonbaugh RE, Mason BA, Friedman CJ et al. Oral granisetron is an effective anti-emetic in patients receiving moderately emetogenic chemotherapy. Proc Am Soc Clin Oncol 1994; 13:437.
23. Heron JF, Goedhals L, Jordaan JP et al. Oral granisetron alone and in combination with dexamethasone: A double-blind randomized comparison against high-dose metoclopramide plus dexamethasone in prevention of cisplatin-induced emesis. Ann Oncol 1994;5:579-584.
24. Tonato M, Roila F, Del Favero A. Mediodology of antiemetic trials: a review. Ann Oncol 1991;2:107-114.
25. Joss RA, Brand BC, Buser KS et al. The symptomatic control of cytostatic drug-induced emesis. A recent history and review. Eur J Cancer 1990;26[suppl 1]:S2-S8.